Comparison of the SARS-CoV-2 spike protein ELISA and the Abbott Architect SARS-CoV-2 IgG nucleocapsid protein assays for detection of antibodies

PLoS One. 2021 Jul 29;16(7):e0255208. doi: 10.1371/journal.pone.0255208. eCollection 2021.

Abstract

Serologic assays developed for SARS-CoV-2 detect different antibody subtypes and are based on different target antigens. Comparison of the performance of a SARS-CoV-2 Spike-Protein ELISA and the nucleocapsid-based Abbott ArchitectTM SARS-CoV-2 IgG assay indicated that the assays had high concordance, with rare paired discordant tests results.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / immunology*
  • COVID-19 / diagnosis*
  • COVID-19 / virology
  • Child
  • Child, Preschool
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Humans
  • Immunoglobulin G / immunology*
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Nucleocapsid / immunology*
  • Nucleocapsid Proteins / immunology*
  • SARS-CoV-2 / immunology*
  • Sensitivity and Specificity
  • Spike Glycoprotein, Coronavirus / immunology*
  • Young Adult

Substances

  • Antibodies, Viral
  • Immunoglobulin G
  • Nucleocapsid Proteins
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2

Grants and funding

The authors received no specific funding for this work.